Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (6904)	7/21/1999 11:28:00 PM
From: Vector1	Read Replies (1) \| Respond to of 9719

Biowa, yes it is. I believe they are pricing on Monday. Since P.P.Morgan is the lead maybe they will get some of the halo effect from the Genentech offering. I can't think of a better place to get approval and establish proof of principal for a oxygen therapuedic than South Africa where the blood supply is seriously tainted. From Hoovers.com Biopure Corporation indicates features for Hoover's Online Members only. -------------------------------------------------------------------------------- 11 Hurley St. Cambridge, MA 02141 Phone: 617-234-6500 Fax: 617-234-6505 Web Site: biopure.com IPO INFORMATION -------------------------------------------------------------------------------- Filing date: May 19, 1999 Expected IPO date: Week of July 26 Exchange: Nasdaq Proposed ticker: BPUR Proposed offer price: $15.50 to $17.50 Shares offered (mil.): 4.5 Offering amount (mil.): $74.3 Post-offering shares (mil.): 22.771 Underwriters: J.P. Morgan & Co.; Adams, Harkness & Hill, Inc.; Robert W. Baird & Co. Incorporated KEY NUMBERS -------------------------------------------------------------------------------- Fiscal Year-End: October 1998 Sales (mil.): $1.1 1998 Income (mil.): $(30.0) Employees: 177 More Financials KEY PEOPLE -------------------------------------------------------------------------------- CEO: Carl W. Rausch CFO: Daniel R. Davis HR: Carolyn R. Fuchs Biopure gives new meaning to blood work. The company makes an artificial blood product based on bovine red blood cells to deliver oxygen to patients with acute blood loss, anemia, or who have had a stroke or a heart attack. Its Hemopure, for humans, and Oxyglobin, for dogs (already approved for veterinary use), are made of purified and processed cow blood, have a two-year shelf life, do not require blood typing, and release more oxygen than a blood transfusion. The blood products also are less viscous than red blood cells, allowing them to flow more easily through partially blocked or constricted blood vessels. Chairman and CEO Carl Rausch owns about 44% of the company. Additional Sources of Information